<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03419689</url>
  </required_header>
  <id_info>
    <org_study_id>BioDIVA (17-5467)</org_study_id>
    <nct_id>NCT03419689</nct_id>
  </id_info>
  <brief_title>Study Looking at Biomarkers in Ovarian Cancer</brief_title>
  <official_title>Biomarker Discovery Project in High Grade Serous Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a sample study that will collect biological samples (blood, tumor tissue, ascites,&#xD;
      and/or other fluids) from gynecological cancer patients for biomarker research. In addition,&#xD;
      the results of the testing done on the samples will be given to the participant's treating&#xD;
      physician who may use the information to guide treatment decisions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">June 8, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 8, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Genomic and immune signatures in terms of progression free survival</measure>
    <time_frame>10 years</time_frame>
    <description>Short term (1-2 years) versus long term (5-10 years) survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genomic and immune signatures in terms of overall survival</measure>
    <time_frame>10 years</time_frame>
    <description>Short term (1-2 years) versus long term (5-10 years) survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genomic and immune signatures in terms of response to treatments</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Genomic and immune signatures in terms of resistance to treatments</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Sample Collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The following samples may be collected during the study:&#xD;
Tumour tissue samples&#xD;
Blood samples&#xD;
Ascites samples&#xD;
Other fluids requiring drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumour tissue collection</intervention_name>
    <description>Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:&#xD;
At the time of diagnosis or progression&#xD;
Any surgical procedures for management of tumour related medical conditions&#xD;
At each subsequent relapse or disease progression</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Blood samples will be taken:&#xD;
At the time of first diagnosis&#xD;
About 1 week after starting any treatment&#xD;
At each radiological response assessment&#xD;
At each subsequent relapse or disease progression</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ascites Collection</intervention_name>
    <description>Ascites will be collected if paracentesis is required during any of the following time points:&#xD;
At the time of diagnosis or progression&#xD;
Any surgical procedures for management of tumour related medical conditions&#xD;
At each subsequent relapse or disease progression</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluid Collection</intervention_name>
    <description>Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.</description>
    <arm_group_label>Sample Collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of stage III or IV high grade serous ovarian, tubal or primary&#xD;
             peritoneal cancer.&#xD;
&#xD;
          -  Must be 18 years of age or older.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.&#xD;
&#xD;
          -  Have a life expectancy greater than or equal to 6 months.&#xD;
&#xD;
          -  Able to provide adequate informed consent.&#xD;
&#xD;
          -  Willing to undergo blood or fluid collection and tumour biopsy&#xD;
&#xD;
          -  Patients enrolled at the time of surgery must agree to have part of their tumour used&#xD;
             for the purpose of the study.&#xD;
&#xD;
          -  Archival tissue must be available for patients that are enrolled at the time of&#xD;
             progression.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Must not have early stage (I and II) high grade serous, tubal or primary peritoneal&#xD;
             cancer.&#xD;
&#xD;
          -  Must not have other tumour histology other than high grade serous.&#xD;
&#xD;
          -  Must not have contraindication to tumour biopsy and/or blood sampling.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Oza, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amit Oza, M.D.</last_name>
    <phone>416-946-2818</phone>
    <email>amit.oza@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Victoria Regional Health Centre</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Jutzi, MD</last_name>
      <phone>705-728-9090</phone>
      <email>jutzil@rvh.on.ca</email>
    </contact>
    <investigator>
      <last_name>Leah Jutzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Elit, M.D.</last_name>
      <email>elitlor@hhsc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josee-Lyne Ethier, M.D.</last_name>
      <email>josee-lyne.ethier@kingstonhsc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanne Weberpals, M.D.</last_name>
      <email>jweberpals@toh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Oza, M.D.</last_name>
      <phone>416-946-2818</phone>
      <email>amit.oza@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

